SCHEMBL458297

SCHEMBL458297

COC(=O)Cc1c(C)nc2c(-c3ccccc3)c(OC(C)(C)C)nn2c1Cl

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.49
TDP1 Q9NUW8 3/20 0.49
NPSR1 Q6W5P4 1/20 0.49
KDM4E B2RXH2 6/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 2/20 0.43
GLA P06280 1/20 0.42
USP2 O75604 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
THRB P10828 3/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 2/20 0.41
BLM P54132 1/20 0.41
TP53 P04637 5/20 0.41
MAPT P10636 2/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL456291 0.75 KDM4E (0.65) L3MBTL1TDP1NPSR1KDM4EHPGD
SCHEMBL6122215 0.75 KMT2A (0.43) L3MBTL1TDP1NPSR1KDM4EHPGD
SCHEMBL459359 0.74 MAPT (0.52) KDM4EHPGDHTTGAASMN1; SMN2
SCHEMBL15226888 0.74 KDM4E (0.52) L3MBTL1TDP1NPSR1KDM4EHPGD
SCHEMBL462614 0.72 KDM4E (0.42) L3MBTL1TDP1NPSR1KDM4EHPGD
SCHEMBL15226807 0.70 KDM4E (0.48) L3MBTL1TDP1NPSR1KDM4EUSP2
SCHEMBL27983065 0.69 KDM4E (0.46) L3MBTL1TDP1KDM4EHPGDHTT
SCHEMBL457958 0.68 HPGD (0.55) L3MBTL1TDP1KDM4EHPGDHTT
SCHEMBL1226461 0.68 KDM4E (0.51) L3MBTL1TDP1NPSR1KDM4EHPGD
SCHEMBL15475631 0.67 NPC1 (0.52) L3MBTL1TDP1KDM4EHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2614064-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2013-07-17 EP disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed